U.S. markets closed

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.3800+0.0600 (+2.59%)
At close: 4:00PM EDT

Clearside Biomedical, Inc.

900 North Point Parkway
Suite 200
Alpharetta, GA 30005
United States
678 270 3631

Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D.Pres, CEO & Director681.67kN/A1952
Mr. Charles A. DeignanChief Financial Officer430.33kN/A1964
Dr. Thomas A. Ciulla M.B.A., M.D.Chief Medical Officer & Chief Devel. Officer460.4kN/AN/A
Ms. Jenny R. KobinHead of Investor RelationsN/AN/A1967
Mr. Leslie B. ZacksGen. Counsel, Chief Compliance Officer & Sec.N/AN/A1969
Mr. Rick McElhenyVP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Clearside Biomedical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.